Adams KK, Baker WL, Sobieraj DM. Myth Busters: Dietary Supplements and COVID-19. Annals of Pharmacotherapy. 2020; 54:(8)820-826

Afrin LB, Weinstock LB, Molderings GJ. Covid-19 Hyperinflammation and Post-Covid-19 Illness May Be Rooted in Mast Cell Activation Syndrome. International Journal of Infectious Diseases. 2020; 100:327-332

Aigner L, Pietrantonio F, Bessa de Sousa DM The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic. Front Mol Biosci. 2020; 7

Barré J, Sabatier J-M, Annweiler C. Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence. Frontiers in Pharmacology. 2020;

Bottari B, Castellone V, Neviani E. Probiotics and Covid-19.: Published online August 12; 2020

Callard F, Perego E. How and why patients made Long Covid. Soc Sci Med. 2021; 268

Charan J, Goyal J, Saxena D, Yadav P. Vitamin D for prevention of respiratory tract infections: A systematic review and meta-analysis. Journal of Pharmacology and Pharmacotherapeutics. 2012; 3:(4)

Dani M, Dirksen A, Taraborrelli P Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. Clin Med (Lond). 2021; 21:(1)e63-e67

Eldanasory OA, Eljaaly K, Memish ZA, Al-Tawfiq JA. Histamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19. Travel Med Infect Dis. 2020; 37

Fidan C, Aydogdu A. As a potential treatment of COVID-19: Montelukast. Med Hypotheses. 2020; 142

Garg P, Arora U, Kumar A, Wig N. The “post-COVID” syndrome: How deep is the damage?. J Med Virol. 2021; 93:(2)673-674

Gasmi A, Tippairote T, Mujawdiya PK Micronutrients as immunomodulatory tools for COVID-19 management. Clin Immunol. 2020; 220

Post-COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clin Exp Res. 2020; 32:(8)1613-1620

Glynne P, Tahmasebi N, Gant V, Gupta R. Long-COVID following mild SARS CoV-2 infection: characteristic T cell alterations and response to antihistamines.: MedRxiv;

Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020; 370

Khan AR, Misdary C, Yegya-Raman N Montelukast in hospitalized patients diagnosed with COVID-19 [published online ahead of print, 2021 Mar 4]. J Asthma. 2021; 1-7

Ladds E, Rushforth A, Wieringa S Developing services for long COVID: lessons from a study of wounded healers. Clinical Medicine. 2021; 21:(1)59-65

Larsen NW, Stiles LE, Miglis MG. Preparing for the long-haul: Autonomic complications of COVID-19 [published online ahead of print, 2021 Jul 3]. Auton Neurosci. 2021; 235

Mahase E. Covid-19: What do we know about “long covid”?. BMJ. 2020; 370

McAuliffe S, Ray S, Fallon E, Bradfield J, Eden T, Kohlmeier M. Dietary micronutrients in the wake of COVID-19: an appraisal of evidence with a focus on high-risk groups and preventative healthcare. BMJ Nutrition, Prevention & Health. 2020; 3:(1)

Morais AHA, Passos TS, Maciel BLL, da Silva-Maia JK. Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection?. Nutrients. 2020; 12:(6)

Mrityunjaya M, Pavithra V, Neelam R, Janhavi P, Halami PM, Ravindra PV. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19. Front Immunol. 2020; 11

Nabavi N. Long covid: How to define it and how to manage it. BMJ. 2020; 370

NHS England. NHS to offer ‘long covid’ sufferers help at specialist centres. 2020. (accessed 24 August 2021)

National Institute of Health and Care Excellence. COVID-19 rapid evidence summary: vitamin D for COVID-19. 2020. (accessed 24 August 2021)

National Institute for Health and Care Excellence; Royal College of General Practitioners; Healthcare Improvement Scotland; SIGN. 2020. (accessed 25 August 2021)

NHS. Long-term effects of coronavirus (long COVID). 2021. (accessed 24 August 2021)

Office for National Statistics. Office for National Statistics. The prevalence of long COVID symptoms and COVID-19 complications. 2020. (accessed 24 August 2021)

Polonikov A. Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients. ACS Infect Dis. 2020; 6:(7)1558-1562

Reznikov LR, Norris MH, Vashisht R Identification of antiviral antihistamines for COVID-19 repurposing. Biochemical and Biophysical Research Communications. 2021; 538:173-179

Sanghai N, Tranmer GK. Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms. Drug Discov Today. 2020; 25:(12)2076-2079

Schäfer A, Muecksch F, Lorenzi JCC Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. Journal of Experimental Medicine. 2020; 218:(3)

Sivan M, Halpin S, Hollingworth L, Snook N, Hickman K, Clifton IJ. Development of an integrated rehabilitation pathway for individuals recovering from COVID-19 in the community. J Rehabil Med. 2020; 52:(8)

Srebro D, Vuckovic S, Milovanovic A, Kosutic J, Vujovic KS, Prostran M. Magnesium in Pain Research: State of the Art. Curr Med Chem. 2017; 24:(4)424-434

Tang C-F, Ding H, Jiao R-Q, Wu X-X, Kong L-D. Possibility of magnesium supplementation for supportive treatment in patients with COVID-19. European Journal of Pharmacology. 2020; 886

Touisserkani SK, Ayatollahi A. Oral Corticosteroid Relieves Post-COVID-19 Anosmia in a 35-Year-Old Patient. Case Reports in Otolaryngology. 2020; 2020:1-2

Vaira LA, Hopkins C, Petrocelli M Efficacy of corticosteroid therapy in the treatment of long-lasting olfactory disorders in COVID-19 patients. Rhinology. 2021; 59:(1)21-25

Yelin D, Margalit I, Yahav D, Runold M, Bruchfeld J. Long COVID-19-it's not over until?. Clin Microbiol Infect. 2021; 27:(4)506-508

Walker A, Pottinger G, Scott A, Hopkins C. Anosmia and loss of smell in the era of covid-19. BMJ. 2020; 370

Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020; 92:(6)568-576

Zafar N, Aslam MA, Ali A Probiotics: Helpful for the prevention of COVID-19?. Biomedical Research and Therapy. 2020; 7:(11)4086-4099

Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020; 92:(5)479-490

Zheng J, Wong LR, Li K COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2021; 589:(7843)603-607

Living with long COVID

02 September 2021
Volume 32 · Issue 9


Post-COVID syndrome, or long COVID, is an increasing problem. Debbie Duncan looks at the evidence for management in primary care

One in five people have symptoms that persist after 5 weeks, and one in ten have symptoms for 12 weeks or longer after an acute COVID-19 infection (Office for National Statistics [ONS], 2020). NICE (National Institute for Health and Care Excellence, 2020) defines this condition as post-COVID syndrome or long COVID. Common symptoms vary from fatigue, shortness of breath, palpitations, insomnia and anxiety and depression and encompasses a plethora of debilitating symptoms (Dani et al, 2021). The new guideline for NICE (2021) recommends that patients presenting with new or ongoing symptoms 4 weeks or later after an initial COVID infection should have the investigations done to rule out acute, life-threatening complications or identify any unrelated diagnosis (NICE, 2021). Garg et al (2020) suggests that long COVID is a multisystem syndrome and needs a multifaceted approach to tackle the physical, cognitive, psychological, social, and vocational aspects of this condition. This article looks at the literature about long COVID and suggests there is a clear pathway for treatment in primary care. All physicians should be equipped to recognise long-COVID and provide supportive management (Dani et al, 2021).

The ONS predict that that one in five people have symptoms that persist after 5 weeks, and one in ten have symptoms for 12 weeks or longer after acute COVID-19 infection (ONS, 2020). NICE defines post-COVID syndrome or long COVID as symptoms that continue more than 12 weeks after a coronavirus infection, which are not explained by another condition NICE (2020).

Despite the fact that one fifth of COVID-19 patients have long COVID, the specific causes remain unclear. What is known is that mast cells are activated by the SARS-CoV-2 virus and the disease is a chronic multisystem disorder with inflammatory action (Afrin et al, 2020; Wang et al, 2020). Certainly following direct viral invasion thrombosis, hyper activation of the immune system and hormonal dysregulation have led to the acute symptoms of COVID-19 but it is unclear what plays a part in long COVID (Yelin et al, 2020). It is also unclear why some people recover quicker than others. Persistent viremia due to weak or absent antibody response, deconditioning, post-traumatic stress and an acute immune response may all contribute to the recovery time (Greenhalgh et al, 2020). The symptoms also vary from person to person but there is an extensive list of common symptoms mirroring the complex impact of COVID-19 and outlined by NICE (2020) (Box 1). It encompasses a plethora of debilitating symptoms which can last for weeks (Dani et al, 2021).

Register now to continue reading

Thank you for visiting Practice Nursing and reading some of our peer-reviewed resources for general practice nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month